Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial.

Autor: Rasmussen BB (AUTHOR), Regan MM (AUTHOR), Lykkesfeldt AE (AUTHOR), Dell'Orto P (AUTHOR), Del Curto B (AUTHOR), Henriksen KL (AUTHOR), Mastropasqua MG (AUTHOR), Price KN (AUTHOR), Méry E (AUTHOR), Lacroix-Triki M (AUTHOR), Braye S (AUTHOR), Altermatt HJ (AUTHOR), Gelber RD (AUTHOR), Castiglione-Gertsch M (AUTHOR), Goldhirsch A (AUTHOR), Gusterson BA (AUTHOR), Thürlimann B (AUTHOR), Coates AS (AUTHOR), Viale G (AUTHOR), BIG 1-98 Collaborative and International Breast Cancer Study Groups (CORPORATE AUTHOR)
Zdroj: Lancet Oncology. Jan2008, Vol. 9 Issue 1, p23-28. 6p.
Databáze: Academic Search Ultimate